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Progesterone is well known as a female reproductive hormone and in particular for its role
in uterine receptivity, implantation, and the maintenance of pregnancy. However, neuroen-
docrine research over the past decades has established that progesterone has multiple
functions beyond reproduction. Within the nervous system, its neuromodulatory and neu-
roprotective effects are much studied. Although progesterone has been shown to also
promote myelin repair, its inﬂuence and that of other steroids on myelination and remyeli-
nation is relatively neglected. Reasons for this are that hormonal inﬂuences are still not
considered as a central problem by most myelin biologists, and that neuroendocrinolo-
gists are not sufﬁciently concerned with the importance of myelin in neuron functions
and viability. The effects of progesterone in the nervous system involve a variety of signal-
ing mechanisms. The identiﬁcation of the classical intracellular progesterone receptors as
therapeutic targets for myelin repair suggests new health beneﬁts for synthetic progestins,
speciﬁcally designed for contraceptive use and hormone replacement therapies.There are
also major advantages to use natural progesterone in neuroprotective and myelin repair
strategies, because progesterone is converted to biologically active metabolites in nervous
tissues and interacts with multiple target proteins. The delivery of progesterone however
represents a challenge because of its ﬁrst-pass metabolism in digestive tract and liver.
Recently, the intranasal route of progesterone administration has received attention for
easy and efﬁcient targeting of the brain. Progesterone in the brain is derived from the
steroidogenic endocrine glands or from local synthesis by neural cells. Stimulating the for-
mation of endogenous progesterone is currently explored as an alternative strategy for
neuroprotection, axonal regeneration, and myelin repair.
Keywords: progesterone, allopregnanolone, progestins, neurosteroids, myelin, multiple sclerosis, oligodendro-
cytes, Schwann cells
INTRODUCTION
Over the past two decades, the pleiotropic effects which steroids
exert throughout the nervous system have become an active
area of investigation in neuroendocrine science. Since the pio-
neering studies of the biosynthesis, mechanisms of action, and
effects of steroids in the brain in the late 1980s and early 1990s,
extensive investigations have improved our knowledge in this ﬁeld.
Abbreviations: 3α-HSD, 3α-hydroxysteroid dehydrogenases; 3β-HSD, 3β-
hydroxysteroid dehydrogenase; 5α-DHP, 5α-dihydroprogesterone; BrdU, bromod-
eoxyuridine; CMT, Charcot–Marie–Tooth diseases; CNS, central nervous system;
DRG, dorsal root ganglia; EAE, experimental autoimmune encephalomyelitis;
ER, estrogen receptor; GABAA receptors, γ-aminobutyric acid type A receptors;
HRT, hormone replacement therapy; IPSCs, inhibitory postsynaptic currents; LPC,
lysolecithin or lysophosphatidylcholine; MBP, myelin basic protein; MCAO, mid-
dle cerebral artery occlusion; MPA, medroxyprogesterone acetate (Provera); OPC,
oligodendrocyte progenitor cells; OPP, oligodendrocyte pre-progenitors; P0, pro-
tein zero; PLP, proteolipid protein; PMP22, peripheral myelin protein-22; PNS,
peripheral nervous system; PR, progesterone receptor; PRE/GRE, progesterone and
glucocorticoid response element; TBI, traumatic brain injury; TSPO, translocase
18 kDa.
Remarkably, experimental studies have recently translated into
clinical trials (Schumacher et al., 2008; Stein and Wright, 2010;
El-Etr et al., 2011).
With the ﬁrst observations that steroids regulate the synthesis of
neurotransmitters and the activity of neurotransmitter receptors,
it became evident that their actions in the brain extendwell beyond
reproduction and adaptation to stress (Luine et al., 1980;Majewska
et al., 1986). Moreover, estradiol was shown to have marked inﬂu-
ences on synaptic and dendritic spine plasticity (Gould et al., 1990;
McEwen, 2001). Neuroprotective effects of both progestagens and
estrogens were then demonstrated in different experimental mod-
els of nervous system injury, ranging from middle cerebral artery
occlusion (MCAO), excitotoxic neuron death, and traumatic brain
injury (TBI) to spinal cord lesions (Garcia-Segura et al., 2001;
Stein, 2001; Wise, 2002; De Nicola et al., 2009).
Soon after the discovery that some steroids, and in particu-
lar pregnenolone and progesterone, can be synthesized de novo
from cholesterol within the nervous system, these so-called “neu-
rosteroids” were proposed to play a role in myelination (Baulieu,
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1997). This hypothesis was based on the observations that: (1)
progesterone is produced by cultures of glial cells incubated in the
presence of steroid precursors; (2) adding progesterone to mixed
glial cell cultures prepared from neonatal rat brains increases the
proportionof oligodendrocytes, themyelinating cells of the central
nervous system (CNS); (3) oligodendrocytes may express proges-
terone receptors (PR), although this particular point remains to
be clariﬁed as no double labeling with cell-speciﬁc markers was
performed (Jung-Testas et al., 1989, 1991). A few years later, it was
demonstrated that progesterone synthesis by Schwann cells, the
myelinating cells of the peripheral nervous system (PNS), plays
an important role in the myelination of peripheral nerves (Koenig
et al., 1995).
The lipid-rich and insulating myelin sheaths, which surround
axons in the vertebrate nervous system, are required for the
rapid saltatory conduction of nerve impulses (Baumann and
Pham-Dinh, 2001; Hartline and Colman, 2007). The impor-
tance of myelin is documented by neurological disorders, ranging
from inherited dysmyelinating diseases characterized by defec-
tive myelin formation, including leukodystrophies and peripheral
neuropathies such as Charcot–Marie–Tooth diseases (CMT), to
acquired demyelinating diseases involving the destruction of exist-
ing myelin sheaths, such as multiple sclerosis. Importantly, recent
research has revealed that myelin, in addition to its role in rapid
nerve conduction, also provides trophic support to axons, essential
for their functional integrity, and the survival of neurons (Yin et al.,
2006; Nave and Trapp, 2008). For this reason, axonal degeneration
and neuron death are common hallmarks of myelin disorders, and
it is urgent to replace lost myelin after nervous tissue lesions.
This review will focus on the role of progestagens in myelin
formation. Initially, the terms “progestagens” or “progestogens”
referred to natural or synthetic steroids which prepare the uterus
for pregnancy. In the light of the multiple functions of proges-
terone, we propose to extend this functional deﬁnition to include
the neuroactivemetabolites of progesterone. The term“progestin,”
which is not used in a consistent manner in the scientiﬁc literature,
will refer here to synthetic progestagens, developed to target the
classical intracellular PR (Schumacher et al., 2007). As a historical
reminder, the term“progestin” initially referred to the ovarian hor-
mone which supports and assists pregnancy, but after its isolation
and identiﬁcation in 1934, the name progesterone was proposed
for common use in the scientiﬁc literature (Stanczyk and Henzl,
2001). Unfortunately, the term progesterone, which should only
designate the“natural”or“bioidentical”hormone, continues to be
used in themedical literature as a generic one for the different types
of natural and synthetic progestagens, thus creating confusion.
MYELINATION AND REMYELINATION IN THE CENTRAL AND
PERIPHERAL NERVOUS SYSTEMS
In the CNS, oligodendrocytes can extend up to 40 processes, each
enveloping an axon stretch with a compact myelin sheath, and
adjacent myelin segments of a same axon may belong to dif-
ferent oligodendrocytes (Baumann and Pham-Dinh, 2001). As
a consequence, the death of a single oligodendrocyte results in
myelin loss and in the interruption of electrical impulses for many
axons. Whereas neuronal regeneration is limited within the CNS,
lost myelin can be replaced after injury or during demyelinating
diseases as part of a natural healing process. This process, named
“remyelination” or “myelin repair,” requires the generation of new
oligodendrocytes from oligodendrocyte progenitor cells (OPC;
Chang et al., 2002; Franklin and FFrench-Constant, 2008). In the
adult brain and spinal cord, OPC are ubiquitous and represent a
large percentage of the total cell population, as much as 9% of cells
in white matter and 3% in gray matter (Nishiyama, 2001; Daw-
son et al., 2003). In response to a demyelinating lesion, adult OPC
start proliferating and are recruited to the demyelinated axons,
where they differentiate into mature, myelin-forming oligoden-
drocytes. The different stages of maturation toward myelinating
oligodendrocytes can be identiﬁed by cell type-speciﬁc markers
(Figure 1A). Our laboratory has isolated from postnatal day 2
rat brains a very early stage of progenitors, named early PSA–
NCAM+ pre-progenitors (early OPP), which still do not respond
to platelet-derived growth factor-AA (PDGF-AA), a key growth
factor of OPC, but instead proliferate in response to epidermal
growth factor, a growth factor for early neural progenitors (Gago
et al., 2003). As discussed later in more detail, early OPP synthe-
size progesterone and its metabolite allopregnanolone, involved
in a complex autocrine loop controlling their proliferation (Gago
et al., 2004).
It is important to draw here attention to differences between
developmental myelination and myelin repair in the adult CNS.
Although both processes share many similarities, and the study of
developmental myelination contributes to our understanding of
myelin regeneration, there are also divergences concerning the role
of transcription and growth factors. Adult OPC are indeed distinct
from the perinatal ones (Fancy et al., 2011; Huang and Franklin,
2011). Importantly, myelin also regenerates in patients with mul-
tiple sclerosis during the early relapsing/remitting stages, but as
the disease progresses, the remyelination of axons becomes insuf-
ﬁcient and repair fails, possibly because of deﬁcient adult OPC
recruitment and differentiation (Kuhlmann et al., 2008). Stim-
ulating these processes has recently been recognized as a major
therapeutic challenge for demyelinating diseases (Franklin and
FFrench-Constant, 2008).
Reciprocal communication between oligodendrocytes, neu-
rons, and astrocytes plays a key role in the formation of newmyelin
sheaths (Talbott et al., 2005; Ishibashi et al., 2006; Simons and Tra-
jkovic, 2006). Thus, steroids may stimulate the myelination and
remyelination of axons directly by acting on oligodendrocytes, or
indirectly via their effects on neurons or astrocytes. However, it is
likely that they act in a concerted manner on multiple neural cell
types.
In the PNS, myelin sheaths are formed by Schwann cells, the
only glial cell type in peripheral nerves. Peripheral and central
myelin also differs in protein content. The two major protein
constituents of CNS myelin are proteolipid protein (PLP) and
myelin basic protein (MBP; Quarles et al., 2006). PLP plays an
important role in myelin membrane stability and sustains axonal
functions (Yin et al., 2006). MBP has many splice variants, which
are developmentally regulated. In adult myelin, the role of the pre-
dominant 18.5 kDa isoform is to maintain the structural integrity
and compaction of the myelin sheaths (Harauz et al., 2009). In
peripheral myelin, the transmembrane protein zero (P0) replaces
PLP as the major protein, although myelin-forming Schwann cells
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FIGURE 1 | Different stages of oligodendrocyte maturation. (A)
Speciﬁc markers allow to identify the differentiation status of cells of
the oligodendrocyte lineage (PSA–NCAM, polysialic acid-neural cell
adhesion molecule; PDGFαR, platelet-derived growth factor receptor
alpha; NG2, a membrane chondroitin sulfate proteoglycan; O4 antigen,
cell surface sulfatide; A2B5 and GD3antigens, cell surface gangliosides;
DM20, splice variant of the proteolipid protein; GalC,
galactocerebroside, enzyme involved in cerebroside metabolism; PLP,
proteolipid protein, MBP, myelin basic protein; MOG, myelin
oligodendrocyte protein). (Adapted from Levine et al., 2001; Gago et al.,
2003 and Ghoumari et al., 2005). (B) Schematic presentation of
progesterone synthesis (3β-HSD activity) and metabolism
(5α-reductase and 3α-HSD activities) by oligodendroglial cells at
different stages of their maturation (adapted from Gago et al., 2001).
also express low levels of PLP (Quarles et al., 2006). Besides its role
in myelin structure, P0 is involved in neuron–glial interactions
(Eichberg, 2002). Mutations in the P0 gene are at the origin of
neuropathies collectively known as Charcot–Marie–Tooth disease
type 1B (CMT1B; Shy,2006). In addition to themajor P0 glycopro-
tein, compact PNS myelin contains peripheral myelin protein-22
(PMP22), which accounts for less than 5% of the total protein.
The functions of PMP22 are not completely understood, but the
protein may be involved in myelin assembly and maintenance
(Quarles et al., 2006). Duplication of one PMP22 allele causes
CMT1A, the most common form of inherited neuropathies and
characterized by the demyelination and loss of axons. On the con-
trary, deletion of one PMP22 allele causes a milder neuropathy
with liability to pressure palsies (Suter and Scherer, 2003). Indeed,
different myelin proteins need to be expressed at precise levels
and ratios to ensure not only the correct formation of myelin
sheaths, but also their stability and maintenance. Thus, already
a small change in the ratio of different myelin proteins can lead
to demyelinating peripheral neuropathies (Giambonini-Brugnoli
et al., 2005). The same is true for the CNS, were disturbed myelin
gene dosage results in severe myelin disorders (Karim et al., 2007).
For this reason, myelin genes are qualiﬁed as dosage-sensitive.
Whereas PNS and CNS myelin proteins are very different,
myelin lipids are qualitatively very similar and only differ quantita-
tively (Quarles et al., 2006). The steroid cholesterol is a major lipid
constituent of the myelin membrane, representing about 25% of
the total myelin lipids, and this explains why 25% of the total
amount of cholesterol present in the human body is localized
to the brain (Björkhem and Meaney, 2004; Chrast et al., 2011).
All nervous system cholesterol is derived from local synthesis by
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glial cells, as the blood–brain-barrier and the blood–nerve bar-
rier are not permeable to the steroid (Jurevics and Morell, 1995;
Morell and Jurevics, 1996; Jurevics et al., 1998). Thus, choles-
terol may be considered as a typical neurosteroid. In the CNS, the
large amounts of cholesterol required for the synthesis of myelin
are produced by the oligodendrocytes themselves. This has been
demonstrated by selectively inactivating in oligodendrocytes the
expression of the squalene synthase, a key enzyme involved in
cholesterol biosynthesis (Saher et al., 2005). Similarly, peripheral
nerves are hypomyelinated if cholesterol biosynthesis is lacking in
Schwann cells (Saher et al., 2009).
There are other fundamental differences between Schwann cell
and oligodendrocyte myelination. Whereas a single oligodendro-
cyte myelinates portions of multiple adjacent axons, Schwann cells
only myelinate one segment of a single axon. Moreover, in con-
trast to oligodendrocytes, Schwann cells are characterized by a
remarkable plasticity. Whereas remyelination in the CNS requires
the recruitment of progenitor cells and their differentiation into
new oligodendrocytes, Schwann cells have the capacity to dedif-
ferentiate and to assume a phenotype similar to immature cells in
response to injury. This process also represents an essential step in
axonal regeneration, as Schwann cells are a major local source of
growth factors and neurosteroids (Mirsky et al., 2008). Peripheral
axons, in contrast to the limited capacity of regeneration of cen-
tral axons, indeed regrow spontaneously after injury thanks to a
permissive environment and the intrinsic regenerative capacity of
neurons (Chen et al., 2007). Once again in contact with the regen-
erating axons, Schwann cells differentiate and form new myelin
sheaths (Fawcett and Keynes, 1990; Chen et al., 2007). Remyelina-
tion is regulated by axonal signals, which differ between Schwann
cells and oligodendrocytes (Chan et al., 2004; Brinkmann et al.,
2008). Schwann cells only express a myelinating phenotype when
they are in contact with large axons producing threshold levels of
neuregulin-1 type III (Michailov et al., 2004).
In both CNS and PNS, myelin formation is also under the
inﬂuence of progesterone, either derived from the steroidogenic
endocrine glands or from local synthesis.A role for progesterone in
myelin formationwas ﬁrst demonstrated in the PNS, and this orig-
inal observation was subsequently extended to the CNS. However,
before discussing the role of progesterone in myelin formation, we
shall examine the different sources of progesterone in the nervous
system.
SOURCES OF PROGESTERONE IN THE CENTRAL NERVOUS
SYSTEM
Progesterone is produced by the corpus luteum of the ovary dur-
ing the proestrous stage of the rodent estrous cycle and during
the luteal phase of the menstrual cycle in women. In pregnancy,
the ovary remains the main source of progesterone in rodents,
whereas in humans, progesterone is mainly produced by the pla-
centa (Arensburg et al., 1999; Tuckey, 2005). Another source of
progesterone are the adrenal glands,where its synthesis is under the
control of adrenocorticotropic hormone (ACTH; Resko, 1969). As
a consequence, the adrenal secretionof progesterone is increased in
response to stress, andprogesterone secretionby the adrenal glands
can become comparable to that of the ovaries in stressed rats (Fajer
et al., 1971; Schaeffer et al., 2008). Inwomen,part of the circulating
progesterone is derived from the adrenal glands, whereas in men,
plasma progesterone is exclusively of adrenal origin (Gutai et al.,
1977; Eldar-Geva et al., 1998). Progesterone carried in the blood-
stream is bound to corticosteroid-binding globulin and albumin
(Klieber et al., 2007). Free progesterone easily crosses the blood–
brain barrier and rapidly diffuses throughout the brain and spinal
cord (Pardridge and Mietus, 1979).
However, progesterone is also a neurosteroid, which means
that it is also synthesized within the nervous system. Thus, in
addition to its endocrine mode of signaling, it acts on neural tar-
get cells via autocrine/paracrine mechanisms. The synthesis and
metabolism of neurosteroids in the vertebrate nervous system
have been extensively reviewed (Baulieu et al., 2001; Mellon and
Vaudry, 2001; Do Rego et al., 2009; Pelletier, 2010). Progesterone
synthesis involves conversion of cholesterol to pregnenolone by
the side-chain-cleaving (scc) cytochrome P450scc, located at the
inner mitochondrial membrane (Figure 2). The translocation
of cholesterol from the outer to the inner mitochondrial mem-
brane is mediated by the translocase 18 kDa (TSPO), the former
peripheral benzodiazepine receptor (Papadopoulos et al., 2006;
Rupprecht et al., 2010). TSPO ligands can increase the biosynthesis
of neurosteroids by stimulating the intra-mitochondrial trans-
port of cholesterol, which is a rate-limiting step in pregnenolone
synthesis. Pregnenolone is then converted to progesterone by a 3β-
hydroxysteroid dehydrogenase (3β-HSD), either in cytoplasm or
mitochondria (Cherradi et al., 1995). Multiple 3β-HSD isoforms
have been isolated: six in mice, four in rats, and two in humans
(Simard et al., 2005). However,most studies of 3β-HSD expression
in the nervous system do not distinguish between the different
isoforms and probes or antibodies recognize multiple isoforms.
Progesterone is metabolized by two steroid 5α-reductases to 5α-
dihydroprogesterone (5α-DHP). The type 1 enzyme is expressed
in the rat brain at all stages of development, whereas the type
2 enzyme shows a more restricted distribution (Melcangi et al.,
1998; Patte-Mensah et al., 2004b). The same enzymes also reduce
deoxycorticosterone to 5α-dihydrocorticosterone and testosterone
to 5α-dihydrotestosterone.
5α-DHP is further metabolized by 3α-hydroxysteroid
oxidoreductases (3α-HSORs) to allopregnanolone (3α,5α-
tetrahydroprogesterone) or bynotwell deﬁned 3β-HSORactivities
to epiallopregnanolone (3β,5α-tetrahydroprogesterone). Whereas
allopregnanolone is a positive allosteric modulator of GABAA
receptors, the effect of epiallopregnanolone is inhibitory (Back-
strom et al., 2005; Belelli and Lambert, 2005; Figure 2). The
3α-HSORactivities involve two types of enzymes: (1) theNADPH-
dependent cytosolic aldo–keto reductases (AKRs), acting in vivo
as 3-ketosteroid reductases and converting 5α-DHP to allopreg-
nanolone; (2) the NAD+-dependent membrane-associated short-
chain dehydrogenases/reductases (SDRs), acting in vivo as 3α-
hydroxysteroid oxidases and converting allopregnanolone back to
5α-DHP (Chetyrkin et al., 2001; Penning et al., 2004; Belyaeva
et al., 2007; Penning, 2011). Whereas rats only have a single ARK
isoform (AKR1C9), also named 3α-HSD because it speciﬁcally
converts 3-ketosteroids to 3α-hydroxysteroids, multiple and less
selective ARK isoforms are expressed in humans and mice (Pen-
ning et al., 2003; Ishikura et al., 2004). The epimerization of allo-
pregnanolone to epiallopregnanolone is catalyzed by a 3(α→ β)
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FIGURE 2 | Progesterone pathways. Cholesterol is converted to
pregnenolone inside the mitochondria by cytochrome P450scc. Pregnenolone
inside the mitochondria or in the cytoplasmic compartment is converted to
progesterone by the 3β-hydroxysteroid dehydrogenases (3β-HSDs). The
conversion of progesterone to 5α-dihydroprogesterone (5α-DHP) is catalyzed
by two 5α-reductase isoforms. 5α-DHP can be metabolized to
allopregnanolone (3α,5α-tetrahydroprogesterone) by 3α-hydroxysteroid
oxidoreductase (3α-HSORs) activities, involving aldo-keto reductases (AKRs)
converting 5α-DHP to allopregnanolone and short-chain
dehydrogenases/reductases (SDRs), converting allopregnanolone back to
5α-DHP. A 3(α→ β) hydroxysteroid epimerase (HSE) catalyzes the
epimerization of allopregnanolone into epiallopregnanolone.
hydroxysteroid epimerase (HSE). It most likely involves two suc-
cessive enzymatic steps: the oxidation of the 3α-hydroxyl group
followed by the reduction of the 3-ketone group to a 3β-hydroxyl
group (Higashi et al., 2004; Belyaeva et al., 2007; Figure 2).
Neural progesterone synthesis was ﬁrst described in glial cell
cultures prepared from neonatal rat brains (Jung-Testas et al.,
1989). Astrocytes in culture were also reported to synthesize
neurosteroids (Mellon and Deschepper, 1993). On the basis of
these observations, it was assumed that neurosteroids within the
brain would be mainly formed by glial cells. However, it became
rapidly evident that progesterone is also synthesized by CNS neu-
rons. Thus, in the frog hypothalamus, 3β-HSD immunoreactivity
was exclusively found in neurons (Mensah-Nyagan et al., 1994).
In the rat brain, Purkinje neurons were identiﬁed as a major
site of progesterone formation, and to express both cytochrome
P450scc and 3β-HSD enzymes (Ukena et al., 1998, 1999). Neu-
rons, astrocytes, and oligodendrocytes isolated from neonatal
rat brains were all shown to express both P450scc and 3β-HSD
enzymes and to produce pregnenolone and progesterone (Zwain
and Yen, 1999). Moreover, expression studies of neurosteroido-
genic enzymes have revealed their wide distribution throughout
the rat brain (Compagnone and Mellon, 2000).
Expression of 5α-reductase type 1 and 3α-HSD mRNA has
been analyzed in detail in the mouse brain, where both enzymes
were shown to colocalize in principal glutamatergic neurons of the
cerebral cortex, hippocampus, olfactory bulbs, and in glutamater-
gic output neurons of the thalamus and amygdala. Both enzymes
are also present in GABAergic output neurons of the striatum
and thalamus as well as in cerebellar Purkinje neurons, consis-
tent with an autocrine/paracrine modulation of GABAA receptor
signaling by locally produced neurosteroids. Surprisingly, none
of the enzymes was detected in astrocytes, considered to be a
major source of neurosteroids (Agis-Balboa et al., 2006). How-
ever, another study reported the presence of the two 5α-reductase
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enzyme isoforms and the unique 3α-HSD (AKR1C9) in neurons,
astrocytes, and oligodendrocytes of the adult rat spinal cord, sug-
gesting that allopregnanolone may also be synthesized by glial cells
(Patte-Mensah et al., 2004b).
The synthesis of progesterone from its direct precursor preg-
nenolone, and its metabolism to 5α-DHP, allopregnanolone, and
epiallopregnanolone, have been analyzed at three major stages
of rat oligodendrocyte maturation described above: early OPP,
OPC,and fully differentiated oligodendrocytes (Figure 1B). In this
study, important differences in progesterone synthesis and metab-
olism were observed between the different developmental stages,
strongly suggesting that progestagens may play an important role
in the generation of new oligodendrocytes and in myelination
(Gago et al., 2001). Both early OPP and OPC, but not the mature
oligodendrocytes produced signiﬁcant amounts of progesterone.
In contrast, in oligodendrocytes, the conversion of progesterone
to 5α-DHP by the type 1 isoform of the 5α-reductase was highest.
These results indicate that adult oligodendrocytes activelymetabo-
lize progesterone derived from the circulation or other neural cells
to 5α-DHP, which may play a role in the regulation of oligoden-
droglial functions and in the maintenance of myelin. They are also
consistent with earlier reports of a very high 5α-reductase activity
in cultured oligodendrocytes and in brain white matter (Melcangi
et al., 1988, 1994; Celotti et al., 1992). The further metabolism
of 5α-DHP to allopregnanolone was about 10 times higher in
the early OPP when compared to the other developmental stages
(Gago et al., 2001).
Extensive mapping of 3β-HSD mRNA in the rat brain by in situ
hybridization revealed its large distribution throughout the brain
in neuronal populations of the olfactory bulb, hypothalamus, sep-
tum, striatum, thalamus, habenula, hippocampus, cerebral cortex,
and cerebellum. Nucleotide sequencing of PCR-ampliﬁed cDNA
fragments indicated expression of 3β-HSD isoform 1 (Guennoun
et al., 1995). Another in situ hybridization study of the develop-
mental expression and localization of 3β-HSD in the rat brain
conﬁrmed the wide distribution of the enzyme in neurons the
day of birth and on postnatal days 7, 14, and 70. Quantitative
in situ hybridization analysis within the hippocampus revealed
a decrease in the expression of 3β-HSD mRNA expression with
progressing age, concomitant with a decrease in hippocampal
progesterone levels measured by gas chromatography/mass spec-
trometry (GC/MS; Ibanez et al., 2003a). The enzyme is also
strongly expressed in neurons throughout the rat spinal cord, in
the large ventral horn motoneurons and in the small dorsal horn
neurons (Coirini et al., 2002).
The above described changes in progesterone synthesis and
metabolism during the maturation of oligodendrocytes, and the
age-dependent modiﬁcations of hippocampal 3β-HSD expression
and progesterone levels raise the question of the synthesis and sig-
niﬁcance of neurosteroids during brain development. Although
there is strong experimental evidence for an important role of
neuroprogesterone in brain development, data are still fragmen-
tary, and a coherent picture is still missing. It is indeed difﬁcult to
distinguish between the effects of progesterone synthesized by the
brain, placenta, or developing gonads and adrenal glands.
Nevertheless, the synthesis and role of neurosteroids in the
developing CNS are an expanding ﬁeld of interest and have been
recently reviewed (Tsutsui et al., 2004; Mellon, 2007; Hirst et al.,
2008). Although an exhaustive appraisal of the signiﬁcance of
neurosteroids during brain development is beyond the scope of
this review, some key observations warrant to be discussed. Inter-
estingly, enzymes involved in the synthesis and metabolism of
progesterone are present in the nervous system from embryonic
life to adulthood, where they are expressed in a region-speciﬁc
manner (Compagnone and Mellon, 2000; Mellon, 2007). Thus,
P450scc protein has been detected by immunocytochemistry as
early as embryonic day 9.5 in the rat nervous system (Com-
pagnone et al., 1995). It has been proposed that progesterone
and its reduced metabolites, produced either by the placenta or
within the brain, may have a neuroprotective role during fetal
and neonatal life, when complications or low oxygen can lead to
brain injury with serious long-term consequences for the neonate.
Indeed, both cytochrome P450scc and 5α-reductase enzymes are
upregulated and levels of allopregnanolone are increased within
vulnerable regions of the developing sheep brain in response to
hypoxia (Nguyen et al., 2003;Hirst et al., 2008).Moreover, endoge-
nous 5α-reducedmetabolites of progesterone provide resistance to
brain damage, as neuron death in the hippocampus resulting from
hypoxia is markedly increased after infusion of the 5α-reductase
inhibitor ﬁnasteride (Yawno et al., 2007).
In cerebellar Purkinje neurons, P450scc expression starts
immediately after their differentiation around birth (Ukena et al.,
1998). During the neonatal period, Purkinje neurons also synthe-
size progesterone and allopregnanolone, and 3β-HSD expression
and activity are highest in the cerebellum between 7 and 14 days of
age (Ukena et al., 1999). At this developmental stage, progesterone
promotes dendritic growth and synaptogenesis in the develop-
ing Purkinje cells via PR signaling (Sakamoto et al., 2001; Tsutsui
et al., 2004). Brain levels of allopregnanolone vary considerably
across development in rats as a result of changes in 5α-reductase
and 3α-HSD expression, with very high levels at birth followed
by steady low levels until adulthood (Grobin et al., 2003; Grifﬁn
et al., 2004). The administration of allopregnanolone to rat pups
at speciﬁc stages results in marked changes in cortical cytoarchi-
tecture and in behavior (Grobin et al., 2006). In a mouse model of
Niemann–Pick type C disease, brain 5α-reductase, and 3α-HSD
activities and allopregnanolone levels were markedly decreased
during postnatal life. Importantly, the replacement of allopreg-
nanolone alleviated and delayed some of the neurodegenerative
features of the disease (Grifﬁn et al., 2004).
Important for our purpose is the observation that hypoxia dur-
ing pregnancy also leads to devastating white matter damage, as
OPC and immature oligodendrocytes are particularly vulnera-
ble (Back et al., 2002). A marked rise in allopregnanolone levels
has been observed in dialysate probes of sheep white matter after
hypoxia, and it has been proposed that this response may be part
of endogenous protective mechanisms (Nguyen et al., 2004; Hirst
et al., 2008). As discussed later, progestagens play a key role in
myelin formation during development.
This rapid and non-exhaustive overview of experimental evi-
dence for the local synthesis of neuroprogesterone within the
CNS requires some cautious considerations. Although taken as
a whole, available experimental data provide convincing evidence
that progesterone can be synthesized by neural cells, both in the
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adult and developing nervous system, individual studies often
reveal large gaps, and results should always be interpreted within
their precise context. Thus, the expression and activity of steroido-
genic enzymes are subject to complex regulations, and they may
be expressed and functional in a deﬁned compartment of the
nervous system only under particular conditions, depending on
environmental inﬂuences, cellular interactions, the presence of
neurotransmitters or neuropeptides, the developmental stage, or
the integrity of the nervous tissue (Do Rego et al., 2009). It is
also important to be aware of some technical constraints. Thus,
the relevance of studies on the formation of neurosteroids by cul-
tured neural cells isolated from embryonic or newborn animals
needs to be veriﬁed in vivo because of the phenotypic plasticity
these cells can exhibit in vitro. Also, although studies limited to
the expression of steroidogenic enzymes by in situ hybridization,
reverse transcriptase-polymerase chain reaction or immunocyto-
chemistry provide valuable information, they do not demonstrate
their functionality.
Additional support for the synthesis and biological signiﬁcance
of progesterone and its metabolites within the CNS has been pro-
vided by in vivo studies. Thus, elevated levels of pregnenolone and
progesterone can be measured in the male rat CNS after removal
of the steroidogenic endocrine glands by castration and adrenalec-
tomy, consistent with their endogenous production (Coirini et al.,
2002). It could be argued that the long-term persistence of steroids
in the brain of adrenalectomized and castrated animalsmay simply
reﬂect retention and accumulation of the lipophilic compounds.
However, a series of studies have demonstrated that levels of preg-
nenolone, progesterone, and allopregnanolone can be increased in
the brains of rats deprived of their steroidogenic endocrine glands
by the administration of TSPO ligands (Korneyev et al., 1993;
Romeo et al., 1993; Serra et al., 1999; Bitran et al., 2000; Verleye
et al., 2005). These ﬁndings show that it is possible to stimulate
the synthesis of neurosteroids in the brain.
Importantly, levels of pregnenolone and progesterone were sig-
niﬁcantly increased in the male rat spinal cord in response to
injury, even in castrated and adrenalectomized rats with unde-
tectable plasma levels of the hormones (Labombarda et al., 2006).
Brain levels of progesterone are also transiently upregulated in
response to TBI, in brain regions proximal, and distal to the
lesion site (Meffre et al., 2007a). In the rat spinal cord, 3β-
HSD mRNA expression was upregulated and the conversion of
pregnenolone to progesterone was markedly increased 3months
after streptozotocin-induced diabetes (Saredi et al., 2005). The
de novo synthesis of neurosteroids has also been demonstrated
in pain pathways, where progesterone and allopregnanolone play
an important role (Mensah-Nyagan et al., 2009). Thus, during
neuropathic pain provoked by sciatic nerve ligature, P450scc was
over-expressed in spinal and supra-spinal pain networks, con-
comitant with an increase pregnenolone and allopregnanolone
synthesis (Patte-Mensah et al., 2004a). Increased levels of prog-
esterone and 3β-HSD expression were also observed within the
brains of dysmyelinating jimpy and shiverer mouse mutants (Le
Goascogne et al., 2000). Taken together, these ﬁndings strongly
suggest that increased progesterone synthesis in the CNS may be
part of endogenous neuroprotective mechanisms and may cor-
respond to a physiological response of neural cells to injury and
degenerative conditions (De Nicola et al., 2009). In addition, neu-
roprogesterone synthesis also shows physiological changes, as for
example during the estrous cycle (Soma et al., 2005).
A major limitation for detecting local changes in brain steroid
levels within a particular physiological or pathological context is
the limited sensitivity of the available analytical methods, either
radioimmunoassay or mass spectrometry coupled to either liquid
or gas chromatography (Liere et al., 2000). Indeed, the amount of
brain tissue required to accurately analyze low levels of neuros-
teroids (about 50–100mg) corresponds to very large numbers of
neural cells (about 35,000 cells per mg), thus precluding the detec-
tion of localized changes (Geisert et al., 2002;Azevedo et al., 2009).
Unfortunately, no analytical procedure allows to measure changes
in neurosteroid levels within small populations of neurons or at
the synaptic level. Similarly, the measure of enzymatic activities
requires the incubation of large amounts of tissue with precursor
steroids.
A particularly sensitive experimental approach to examine the
signiﬁcance of local changes in brain steroids within a particular
physiological and pathophysiological context is the combination
of electrophysiological recordings with the inhibition or stimula-
tion of neurosteroid biosynthetic pathways. Such studies have in
fact provided strong evidence for an important role of the local
brain metabolism of steroids in the regulation of neuronal func-
tions, and in particular for the role of neurosteroids as endogenous
autocrine/paracrine modulators of GABAA receptors. They also
suggest the presence of endogenous neurosteroid tones within
speciﬁc brain regions (Lambert et al., 2009). In most of these
studies, the measure of inhibitory postsynaptic currents (IPSCs)
was used to evaluate the inﬂuence of locally synthesized 3α,5α-
neurosteroids on GABAA receptor activity. Thus, the systemic
administration of the 5α-reductase inhibitor SKF105111in mice
reduced the decay of miniature IPSCs recorded from cortical neu-
rons (Puia et al., 2003). The application of the 3α-HSD inhibitors
medroxyprogesterone acetate (MPA=Provera) or indomethacin
to rat hippocampal slices uncovered a neurosteroid tone in dentate
gyrus granule cells, enhancing the activity of both synaptic and
extrasynaptic GABAA receptors (Belelli and Herd, 2003). Dur-
ing postnatal development, TSPO-mediated synthesis of 3α,5α-
reduced neurosteroids within speciﬁc lamina of the rat spinal
dorsal horns results in miniature IPSCs with slow decay kinet-
ics. Importantly, this inhibitory neurosteroid tonus is reactivated
in the adult spinal cord in response to peripheral inﬂammation,
when it is involved in analgesic processes (Keller et al., 2004;
Inquimbert et al., 2008). Stimulation of neurosteroid synthesis
with the selective TSPOagonist XBD173 enhanced both the ampli-
tude and duration of evoked IPSCs recorded from neurons of the
medial prefrontal cortex, and this effect could be blocked by the
5α-reductase inhibitor ﬁnasteride (Rupprecht et al., 2009). The
in vivo efﬁcacy of some TSPO ligands at increasing brain levels
of allopregnanolone, a neurosteroid with anxiolytic properties,
has generated interest in their therapeutic potential for the treat-
ment of anxiety disorders (Verleye et al., 2005; Rupprecht et al.,
2009, 2010). However, allopregnanolone displays a broad spec-
trumof psychopharmacological properties. Thus, an increase in its
brain, cerebrospinal ﬂuid, and plasma levels of allopregnanolone
in response to ﬂuoxetine (Prozac®) treatment has been proposed
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to play a role in the antidepressant actions of the drug (Uzunova
et al., 2006).
An interesting example of neurosteroid-dependent neuronal
plasticity and regulation of inhibitory inputs to neurons has been
reported for the auditory midbrain. After selectively blocking the
GABAergic innervation of the central nucleus of the inferior col-
liculus by afferents of the dorsal nucleus of the lateral lemniscus,
enhanced local production of allopregnanolone provided com-
pensation by increasing the efﬁcacy of the other inhibitory inputs
(Saalmann et al., 2006).
Over the past few years, evidence has accumulated that prog-
esterone and its metabolites are also synthesized in the human
nervous system (Stoffel-Wagner, 2001; Weill-Engerer et al., 2002;
Schumacher et al., 2003). The presence of cytochrome P450scc
was ﬁrst detected in the human brain by immunocytochemistry
(Le Goascogne et al., 1989), and subsequently several studies have
described the presence of cytochrome P450scc mRNA in different
brain regions (Beyenburg et al., 1999; Watzka et al., 1999; Inoue
et al., 2002; Yu et al., 2002). The type II isoform of the human
3β-HSD is largely expressed in different parts of the brain and
spinal cord (Inoue et al., 2002; Yu et al., 2002). Also, the enzymes
necessary for the metabolism of progesterone are present in the
human brain (Steckelbroeck et al., 2001; Stoffel et al., 2003).
SOURCES OF PROGESTERONE IN THE PERIPHERAL
NERVOUS SYSTEM
Progesterone present in the bloodstream also crosses the blood–
nerve barrier and easily reaches neural cells in peripheral nerves
and dorsal root ganglia (DRG). In addition, there is also evidence
for neuroprogesterone synthesis by neurons and Schwann cells in
the PNS. Thus, levels of pregnenolone were found to be higher in
male rat sciatic nerves than in plasma, and they were not reduced
by castration and adrenalectomy, strongly suggesting a local syn-
thesis of the direct precursor of progesterone independent of
glandular sources. Cultured Schwann cells isolated from neona-
tal rat sciatic nerves indeed converted 25-hydroxycholesterol, a
cholesterol metabolite which easily crosses cell membranes, to
pregnenolone (Akwa et al., 1993).
As for the CNS, potential links between neurosteroidogen-
esis and myelination have been reported for the PNS. Thus,
cytochrome P450scc and 3β-HSD mRNA were found to be
markedly upregulated in myelinating cocultures of DRG neu-
rons and Schwann cells, but they were exclusively observed in
Schwann cells (Chan et al., 1998, 2000). It was then shown, by
using different coculture systems, that 3β-HSD expression and
progesterone synthesis by Schwann cells are dependent on the
presence of neurons. Indeed, levels of 3β-HSDmRNAand the con-
version of [3H]pregnenolone to [3H]progesterone were extremely
low in puriﬁed Schwann cells prepared from neonatal rat sciatic
nerves. However, 3β-HSD expression and activity were markedly
induced in Schwann cells by the presence of DRG neurons (Robert
et al., 2001). Interestingly, a direct contact with sensory neurons
was not required for the induction of progesterone synthesis in
Schwann cells, but a diffusible neuronal factor was sufﬁcient. This
was demonstrated by using a coculture system in which Schwann
cells and sensory neurons were cultured together, but separated by
a microporous membrane. Interestingly, the induction of 3β-HSD
in Schwann cells by a diffusible neuronal signal was very slow and
became maximal only after 18 days of coculture (Robert et al.,
2001).
Although the diffusible factor has not been identiﬁed, it was
neuron-speciﬁc as neither the presence of ﬁbroblasts, nor of a
human liver cell line, induced 3β-HSD expression in Schwann
cells. However, although a diffusible neuronal signal was sufﬁcient
to induce progesterone and 5α-dihydroprogesterone synthesis in
Schwann cells, the formation of allopregnanolone required a direct
contact with DRG neurons. Thus, both diffusible and contact-
mediated interactions between Schwann cells and neurons are
involved in the regulation of neurosteroid formation. This is
consistent with the previously reported regulation of Schwann
cell functions by neurons either via direct contact or diffusible
molecules (Bolin and Shooter, 1993).
A role of neurons in the regulation of 3β-HSD expression was
also demonstrated in vivo in the rat sciatic nerve. While 3β-HSD
mRNA was present in the intact nerve, it could no longer be
detected 3 or 6 days after cryolesion, when axons had degenerated.
After 15 days, when Schwann cells established new contacts with
the regenerating axons, the enzyme was again re-expressed. After
nerve transection, which does not allow axonal regeneration, 3β-
HSD mRNA remained undetectable. Importantly, the regulation
of 3β-HSD mRNA after sciatic nerve lesion paralleled the expres-
sion of P0 and PMP22 mRNA, supporting an important role of
locally formed progesterone in myelination (Robert et al., 2001).
As Schwann cells not only synthesize progesterone,but also express
the intracellular PR, the neurosteroidmay be part of autocrine reg-
ulatory mechanisms involved in myelination (Jung-Testas et al.,
1996).
Schwann cells are not the only source of progesterone in
the PNS. Indeed, sensory neurons isolated from embryonic rat
DRG also express the 3β-HSD and convert [3H]pregnenolone
to [3H]progesterone. Moreover, when cultured under different
conditions, DRG neurons produced about 5–10 times more prog-
esterone than Schwann cells (Guennoun et al., 1997). Under the
experimental conditions tested,DRGneurons furthermetabolized
progesterone to 5α-dihydroprogesterone, but unlike Schwann
cells, they did not produce allopregnanolone. Neurons and
Schwann cells puriﬁed from the DRG of 6week-old-male rats
showed a similar pattern of pregnenolone and progesterone
metabolism than cells isolated from 18-day-old embryos. The
activity of the 3β-HSD has been characterized in homogenates
prepared from adult rat sciatic nerves by quantifying the conver-
sion of [3H]pregnenolone to [3H]progesterone. The calculated
Km value of 3β-HSD activity was about 1μM, thus close to the
values reported for the 3β-HSD type 1 isoform (Coirini et al.,
2003a,b).
The absence of allopregnanolone formation by embryonic
DRG neurons in culture contrasts with immunocytochemical
in vivo observations of the 3α-HSD in both DRG neurons and
Schwann cells. Moreover, allopregnanolone is synthesized in DRG,
and its production is increased in response to sciatic nerve con-
striction injury, consistent with an important role of locally pro-
duced allopregnanolone in the regulationof nociceptive functions.
Thus, during the development of inﬂammatory pain, increased
formation of allopregnanolone in lamina II of the spinal dorsal
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horn increased synaptic inhibition mediated by GABAA receptors
and limited thermal hyperalgesia, but not mechanical allodynia
(Poisbeau et al., 2005). Furthermore, inhibition of 3α-HSDexpres-
sion inDRGexacerbated thermal andmechanical pain perceptions
(Patte-Mensah et al., 2010). Allopregnanolone may be synthesized
de novo from cholesterol within DRG, as a functional P450scc
enzyme is present and upregulated in response to neuropathic
pain (Patte-Mensah et al., 2003).
STIMULATION OF PERIPHERAL MYELINATION BY
PROGESTERONE
A role of progesterone and its local synthesis in myelin repair has
been shown in the regenerating mouse sciatic nerve after cryole-
sion (Koenig et al., 1995; Table 1). In response to local freezing,
axons and their accompanying myelin sheaths rapidly degenerate
within the frozen zone and in the segment distal to the lesion site
by a process known as “Wallerian degeneration.” It is now well
established that the degeneration of peripheral axons in response
to injury is an active process, corresponding to an active axon
destruction program distinct from apoptosis (Coleman and Free-
man,2010).However,whereas axons degenerate after cryolesion of
the sciatic nerve, the basal lamina tubes remain intact, and provide
an appropriate environment and support for rapid regeneration
of the damaged nerve ﬁbers. In the zone of freeze injury, Schwann
cells start remyelinating the regenerating axons within 1week, and
after 2 weeks, the myelin sheaths reach approximately one-third of
their ﬁnal size. During this period, local application of the 3β-HSD
inhibitor trilostane or the PR antagonist mifepristone (RU486) to
the regenerating nerve ﬁbers inhibited their remyelination. The
inhibitory effect of trilostane could be reversed by the simulta-
neous administration of progesterone, thus demonstrating a role
of locally synthesized progesterone in myelin formation. More-
over, myelination of axons was increased when progesterone was
added to DRG explant cultures (Koenig et al., 1995). Later, it was
shown that adding progesterone to cocultures of Schwann cells
and neurons enhances the rate of myelin formation (Chan et al.,
1998).
In myelinating cocultures of Schwann cells and DRG neu-
rons, PR immunostaining was only detected in the neurons, and
adding progesterone to the culture medium induced neuron-
speciﬁc genes. These observations suggested that progesterone
may indirectly stimulate Schwann cell myelination by acting on
neurons (Chan et al., 2000). Such an indirect signaling mecha-
nism would not be further surprising, as the formation of myelin
sheaths is tightly controlled by axonal signals in the PNS. It is
however likely that progesterone promotes myelination by acting
on multiple cellular targets, and also directly on Schwann cells.
Progesterone has indeed been shown to activate the promoters of
peripheral myelin genes in puriﬁed cultures of Schwann cells iso-
lated form neonatal rat sciatic nerves (Désarnaud et al., 1998). In
this study, Schwann cells were transiently transfectedwith reporter
constructs in which luciferase expression was controlled by the
promoter regions of either the P0 or PMP22 gene. Expression of
the PMP22 gene is driven by two alternate promoters P1 and P2,
of which only the ﬁrst is involved in myelination (Suter et al.,
1994). Under our experimental conditions, progesterone stimu-
lated the promoter of P0 and promoter P1, but not promoter
P2, of PMP22. In addition to this promoter selectivity, the effect
of progesterone was steroid-speciﬁc, as it could be mimicked by
the selective PR agonist ORG 2058, but neither by estradiol nor
testosterone. Moreover, progesterone activated the myelin gene
promoters when they were transfected into Schwann cells, but
into human T47D breast cancer cells, in spite the fact that this cell
line constitutively expresses high levels of functional PR. Taken
together, the promoter-, steroid-, and cell-speciﬁcity suggests that
the transcriptional effects of progesterone on PMP genes may be
of physiological relevance (Désarnaud et al., 1998).
The observation that the selective progestin ORG 2058 stim-
ulated P0 and PMP22 promoter activities is consistent with an
important role of the PR. In primary cultures of puriﬁed neonatal
rat Schwann cells, the presence of the PR was indeed detected by
whole cell binding assays with [3H]ORG 2058 and by immunocy-
tochemistry (Jung-Testas et al., 1996). However, in another study,
no signiﬁcant PR expression and activity could be measured in
rat Schwann cells kept for a long time in culture, as well as in
various Schwann cell lines (Groyer et al., 2006). The discrepancy
between these results could be explained by a tightly regulated
expression of PR in Schwann cells. Thus, steroid receptor expres-
sion in puriﬁed Schwann cells decreases with time (unpublished
observation). Also, PR are inducible by estrogen in Schwann cells
cultured together with DRG neurons, but not in puriﬁed cultures
of Schwann cells (Jung-Testas et al., 1996; Thi et al., 1998). How-
ever, detecting receptor mRNA, protein or ligand binding is not
sufﬁcient to conclude that a receptor is functional. Indeed, low
levels of steroid receptors may not be sufﬁcient to trigger biologi-
cal activity, and threshold levels of expression may be required for
steroid responsiveness (Okret et al., 1991). Deﬁning the precise
role of the Schwann cell PR in vivo will require its cell-speciﬁc and
conditional inactivation.
Another important question is whether the P0 and PMP22
genes are direct targets of progesterone, or whether other PR tar-
get genes mediate the promyelinating effects of the hormone. It
has indeed been proposed that progesterone may indirectly acti-
vate the P0 and PMP22 promoters, as no progesterone response
elements (PRE/GRE) were identiﬁed in their sequences (Désar-
naud et al., 1998). However, it is always difﬁcult to exclude the
involvement of responsive DNA sites in the effects of steroids, and
the presence of two sequences within the P0 promoter region pre-
senting about 40% homology with consensus PRE/GRE has been
reported, although their functionality has not been tested (Mag-
naghi et al., 1999). Whatever, in the light of recent advances in our
understanding of PR-dependent regulation of gene expression,
the question of the presence or absence of hormone response ele-
ments within myelin genes or their promoter regions is no longer
relevant. Thus, PR can regulate gene transcription by binding to
very remote cis-regulatory sites and act at long distances (Deblois
and Giguere, 2008). Alternatively, PR may alter gene expression by
non-classical mechanisms, either by tethering with other nuclear
transcription factors or by interacting with extra-nuclear kinases
(Daniel et al., 2009).
Expression of P0 has been shown to be increased by proges-
terone and 5α-dihydroprogesterone treatment in the sciatic nerve
in vivo and in cultured Schwann cells. On the contrary, the expres-
sion of PMP22 was found to be stimulated by the progesterone
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Table 1 | Effects of progestagens on myelination/remyelination.
Effects Treatments Doses Experimental systems Reference
PERIPHERAL NERVOUS SYSTEM
↑ Myelination of axons Progesterone 20 nM DRG explant cultures (rat) Koenig et al. (1995)
↑ Remyelination of axons Progesterone 100μg local After freeze lesion sciatic nerve (mouse) Koenig et al. (1995)
↓ Remyelination axons Mifepristone 100μg local After freeze lesion sciatic nerve (mouse) Koenig et al. (1995)
↑ Rate of myelination Progesterone 100 nM Schwann cell and DRG neurons (rat) Chan et al. (1998)
↑ Rate of myelination Promegestone 10 nM Schwann cell and DRG neurons (rat) Chan et al. (1998)
↓ Rate of myelination Mifepristone 100 nM Schwann cell and DRG neurons (rat) Chan et al. (1998)
↑ P0 and PMP22 transcription Progesterone 1 nM and 1μM Transfected Schwann cells in culture (rat) Désarnaud et al. (1998)
↑ P0 and PMP22 transcription ORG 2058 1μM Transfected Schwann cells in culture (rat) Désarnaud et al. (1998)
↑ P0 and PMP22 transcription Mifepristone 10μM Transfected Schwann cells in culture (rat) Désarnaud et al. (1998)
↑ P0 expression Progesterone,
5α-DHP
1mg, sc
injections
Sciatic nerve (rat) Melcangi et al. (1999, 2003)
↑ P0 expression Progesterone,
5α-DHP
10nM Schwann cell cultures (rat) Melcangi et al. (1999, 2003)
↑ PMP22 expression Allopregnanolone 1mg, sc
injections
Sciatic nerve (rat) Melcangi et al. (1999, 2003)
↑ PMP22 expression Allopregnanolone 10 nM Schwann cell cultures (rat) Melcangi et al. (1999, 2003)
↑ PMP22 expression Progesterone 20mg/kg
(repeated)
Sciatic nerve in vivo (rat) Melcangi et al. (1999, 2003)
↓ PMP22 expression Onapristone 20mg/kg
(repeated)
Sciatic nerve in vivo (rat) Melcangi et al. (1999, 2003)
CENTRAL NERVOUS SYSTEM
Effects Progestagens Treatments Experimental systems Reference
↑ Number of oligodendrocytes Progesterone 100 nM Mixed cultures brain glial cells (rat) Jung-Testas et al. (1989)
↑ Myelination of axons Progesterone,
Allopregnanolone
20μM Cerebellar slice in culture (rat, mouse) Ghoumari et al. (2003)
↑ Oligodendrocyte branching Progesterone 100 nM Cultured rat oligodendrocytes (rat) Marin-Husstege et al. (2004)
↑ Proliferation of early OPP Allopregnanolone 10 nM PSA–NCAM progenitors (rat) Gago et al. (2004)
↑ OPC proliferation, differentiation Progesterone 20μM Cerebellar slice cultures (rat) Ghoumari et al. (2005)
↑ Remyelination of axons Progesterone 20μM LPC demyelinated brain slices (rat, mouse) Hussain et al. (2011)
↑ Remyelination of axons Nestorone 20μM LPC demyelinated brain slices (rat, mouse) Hussain et al. (2011)
No effect on axon remyelination Medroxyproge
sterone acetate
20μM LPC demyelinated brain slices (rat, mouse) Hussain et al. (2011)
↑ OPC proliferation, differentiation Progesterone 16mg/kg/day
sc
Injured spinal cord (rat) Labombarda et al. (2009)
↑ Remyelination of axons Progesterone sc pellets EB demyelinated cerebellar peduncle (rat) Ibanez et al. (2004)
↓ Demyelination of axons Progesterone
(P)+Estradiol (E2)
P: 25μg per
injection
Cuprizone demyelinated CC (mouse) Acs et al. (2009)
↓ Demyelination, disease severity Progesterone sc pellets MOG-induced EAE (female mice) Garay et al. (2007, 2009)
↓ Disease severity, inﬂammation Progesterone sc pellets MOG-induced EAE (female mice) Yates et al. (2010)
↓ Neurological deﬁcits Progesterone 4mg/kg per
injection
Myelin-induced EAE (male rats) Yu et al. (2010)
↑ Disease severity Medroxyproge
sterone acetate
Oral EAE Arnason and Richman. (1969)
↑ Disease severity, neuron death Progesterone sc silastic
implants
MBP-induced EAE (female rats) Hoffman et al. (2001)
CC, corpus callosum; DRG, dorsal root ganglia; EAE, experimental autoimmune encephalomyelitis; EB, Ethidium bromide, DNA intercalating agent, kills cells but spares
axons; LPC, lysophosphatidylcholine, kills oligodendrocytes but spares axons; Medroxyprogesterone acetate (MPA, Provera): progestin, pregnane, non-selective PR
agonist; Mifepristone (RU486): selective progesterone receptor modulator (SPRM), also antagonist of the glucocorticoid receptor; MOG, myelin oligodendrocyte
glycoprotein; Nestorone: progestin, 19-norpregnane, PR agonist; Onapristone (ZK 98299): selective PR antagonist; ORG 2058: progestin, PR agonist; Promegestone
(R5020): progestin, 19-norpregnane, PR agonist; sc, subcutaneous.
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metabolite allopregnanolone acting via GABAA receptors under
the same experimental conditions (Melcangi et al., 1999, 2003,
2005; Table 1). Adding to the complexity of myelin gene regula-
tion, glucocorticoids have also been shown to activate both P0 and
PMP22 promoters (Désarnaud et al., 2000). As alreadymentioned,
myelin protein genes are dosage-sensitive and require tightly coor-
dinated expression. It is difﬁcult to understand how this could be
achieved if different genes would be directly and independently
targeted by multiple hormones. It is thus appealing to propose
indirect steroidal inﬂuences onmyelin formation, involving amas-
ter regulatory signaling pathway for the coordinated expression of
myelin genes.
In a transgenic rat model of CMT1A overexpressing PMP22,
PR signaling was shown to enhance the disease phenotype. Indeed,
progesterone treatment further increased PMP22 mRNA levels
and had adverse effects on disease symptoms,whereas administra-
tion of the selective PR antagonist onapristone normalizedPMP22
expression and improved the CMT1A phenotype. These data sug-
gest that the Schwann cell PR may be a promising pharmacological
target for the therapy of CMT1A (Sereda et al., 2003). Interest-
ingly, it was then shown that long-term anti-progestin treatment
of CMT1A rats prevents axonal loss, which is characteristic of the
neuropathy, but in the absence of a beneﬁcial inﬂuence on myelin.
Thus, Schwann cell defects can result in axon damage independent
of myelin loss (Meyer zu Horste et al., 2007).
STIMULATION OF CENTRAL MYELINATION BY
PROGESTERONE
As reported above, early OPP synthesize progesterone and pro-
duce its reduced metabolite allopregnanolone, a potent positive
allosteric modulator of GABAA receptors. Progesterone indeed
indirectly stimulates the proliferation of early OPP through its
metabolite allopregnanolone via a bicuculline-sensitive mecha-
nism involving GABAA receptors (Gago et al., 2004). Importantly,
the earlyOPP expressGABAA receptors and also synthesizeGABA.
These results reveal complex autocrine/paracrine loops in the con-
trol of early OPP proliferation, involving interactive neurosteroid
and GABA signaling (Figure 3).
In organotypic slice cultures of 7-day-old rat cerebellum, prog-
esterone was found to also stimulate the proliferation of OPC at
later stages of maturation, when they become OPC expressing the
chondroitin sulfate proteoglycan NG2 and pre-oligodendrocytes
co-expressing both NG2 and O4 antigens (Ghoumari et al., 2005;
Table 1). Contrary to the early OPP, progesterone stimulated the
proliferation of pre-oligodendrocytes via a PR-dependent mech-
anism, as its mitogenic effect was inhibited by the PR antagonist
mifepristone and could not be mimicked by allopregnanolone,
even at a high concentration (Ghoumari et al., 2005). There
may thus be a developmental shift in mitogenic signaling: allo-
pregnanolone acting via GABAA receptors in early OPP and
progesterone acting via intracellular PR in pre-oligodendrocytes.
However, it remains to be clariﬁed whether progesterone exerts
its mitogenic effects by directly acting on pre-oligodendrocytes in
the cerebellar slices, or indirectly by acting on neurons or astro-
cytes. Myelination is indeed inﬂuenced by a crosstalk between
neurons and oligodendrocytes and is dependent on axonal func-
tions (Trapp and Nave, 2008). In this context, it is interesting to
FIGURE 3 | Autocrine regulatory loop regulating the proliferation of
early oligodendrocyte pre-progenitors (early OPP). Epidermal growth
factor (EGF) is a potent mitogen for early OPP. These cells express GABAA
receptors and synthesize GABA, which also stimulates their proliferation.
Moreover, early OPP synthesize allopregnanolone, which at nanomolar
concentrations, increases their proliferation via the modulation of GABAA
receptors. Thus, OPP proliferation is regulated by two interacting autocrine
signaling pathways (3α-HSOR, 3α-hydroxysteroid oxidoreductase; 3β-HSD,
3β-hydroxysteroid dehydrogenase; 5α-DHP, 5α-dihydroprogesterone; GAD,
glutamate decarboxylase; adapted from Gago et al., 2004).
remind the neuroprotective functions of progesterone and allo-
pregnanolone and their regenerative potential (Wang et al., 2008).
Astrocytes are also particularly interesting targets of progesterone,
as progesterone stimulates growth factor production by these cells
via PR signaling (Lacroix-Fralish et al., 2006;Chesik andDe,2010).
Interestingly, between 3 and 7 days in culture, a drop in the
number of the NG2+/O4+ pre-oligodendrocytes in the cerebellar
slice cultures was associatedwith amarked increase inO4+/GalC+
premyelinating and myelinating oligodendrocytes. This observa-
tion suggests that progesterone may not only stimulate the pro-
liferation of progenitor cells, but also their differentiation into
mature oligodendrocytes (Ghoumari et al., 2003, 2005).
That progesterone indeed promotes the differentiation of OPC
intomyelinating oligodendrocytes has been recently demonstrated
in adult male rats after spinal cord injury (Labombarda et al.,
2009). Oligodendrocytes are very sensitive to different types of
insults, and their loss followed by the demyelination of axons
is a hallmark of CNS injury (Lytle and Wrathall, 2007; Siegen-
thaler et al., 2007). Three days after spinal cord transection, the
number of oligodendrocytes was reduced by half, accompanied by
a concomitant marked increase in the number of OPC. Shortly
after injury, progesterone treatment further increased the num-
ber of OPC and stimulated their proliferation as determined
by the incorporation of bromodeoxyuridine (BrdU). The dif-
ferentiation of OPC which had incorporated BrdU during the
ﬁrst 3 days after injury was examined after 21 days by analyzing
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the colocalization of retained BrdU and myelin-speciﬁc markers.
Thiswindow-labeling strategy alloweddemonstrating that proges-
terone is required for the differentiation of OPC into oligodendro-
cytes (Labombarda et al., 2009). Indeed, in the absence of proges-
terone treatment,OPC failed to differentiate into oligodendrocytes
after spinal cord injury.
A role of progesterone in OPC differentiation and myelin pro-
tein gene expression is a major ﬁnding, as compromised remyeli-
nation observed at advanced stages of multiple sclerosis may be
caused by defectiveOPCmaturation, rather than by impairedOPC
recruitment (Franklin and Kotter, 2008). Whether the differenti-
ating effect of progesterone on OPC reﬂects direct actions or is
indirectly mediated via other cell types remains to be clariﬁed.
Indeed, after spinal cord injury, progesterone not only stimulates
the generation of new oligodendrocytes but has also a beneﬁ-
cial inﬂuence on astrogliosis and neuroinﬂammatory responses
(Labombarda et al., 2011).
Then, the important question arises whether the effects of
progesterone on OPC proliferation and differentiation translate
into increased myelin formation and improved axon remyelina-
tion. The effects of progesterone on developmental myelination
were again investigated in slice cultures of postnatal day 7 (P7) rat
cerebellum (Ghoumari et al., 2003; Table 1). This developmental
stage corresponds to a period of intense myelination and also of
increased local progesterone synthesis in the cerebellum (Notter-
pek et al., 1993; Ukena et al., 1999). Adding 10–50μM of proges-
terone to the culture medium for 7 days accelerated the process of
myelin formation, evaluated by analyzing MBP immunostaining.
The micromolar concentrations of progesterone used in this study
may seem very elevated, but in this culture system, only part the
hormone penetrates the 350μM thick cerebellar slices, which are
cultured on top of a microporous membrane and not submerged
by the medium (Ghoumari et al., 2003). As for the stimulation
of pre-oligodendrocyte proliferation, the promyelinating effect of
progesterone involved the classical intracellular PR, as it could
be mimicked by the very selective PR agonist R5020 and blocked
by the PR antagonist mifepristone. Moreover, progesterone treat-
ment did not stimulate myelination in cerebellar slices sampled
fromPR knockoutmice (Figure 4A). However, this study also pro-
vided evidence for an additional involvement of GABAA receptor
modulation by allopregnanolone: progesterone was metabolized
to allopregnanolone in the cerebellar slices, and preventing its for-
mation with the 5α-reductase inhibitor L685-273 or inhibiting
GABAA receptors with bicuculline decreased the promyelinating
efﬁcacy of progesterone (Ghoumari et al., 2003). Nevertheless, PR
play a key role, as no promyelinating effects of progesterone were
observed in PR knockout mice.
The effects of progesteroneonmyelin repair can alsobe tested in
organotypic cultures of cerebellar slices.As alreadymentioned, it is
always necessary to verify whether signaling mechanisms involved
in the regulation of myelin sheath formation during development
become again operational during the remyelination of axons after
a demyelinating insult. Demyelination can be induced in organ-
otypic slice cultures of the rat and mouse cerebellum by exposing
them to lysolecithin (lysophosphatidylcholine, LPC). This experi-
mental system is useful to test the remyelinating efﬁcacy molecules
and to analyze underlying signaling mechanisms (Birgbauer et al.,
FIGURE 4 | Intracellular progesterone receptors are key limiting factors
in progesterone-driven myelin formation. (A) Role of progesterone
receptors (PR) in developmental myelination. PR is necessary for the
stimulation of myelin basic protein (MBP) expression by progesterone,
analyzed by quantifying MBP immunostaining in organotypic cultures of
cerebellar slices taken from postnatal day 7 mice and cultured for 7 days in
the absence (control) or presence of progesterone (20μM). (B) PR is also
necessary for the stimulation of myelin repair by the selective progestin
Nestorone (20μM). Cerebellar slices from postnatal day 10 mice were
cultured for 7 days to allow extensive myelination of axons. The slices were
then demyelinated by treating them overnight with lysolecithin, and they
were cultured for an additional 4 days in the absence (Lyso) or presence of
nestorone before analyzing MBP immunostaining. Cerebellar slices were
taken from wild-type PR+/+ mice, heterozygous PR+/− mice or homozygous
knockout PR−/− mice. Results are expressed as means±SEM.
***p ≤0.001; Newman–Keuls tests after one-way ANOVA when compared
to the corresponding control; ns, non-signiﬁcant.
2004; Mi et al., 2009; Miron et al., 2010). To determine whether
progesterone also promotes the remyelination of axons, cerebellar
slices taken from postnatal day 10 (P10) rats were cultured for
7 days in vitro to allow axons to become myelinated. They were
then treated overnight with lysolecithin to induce the demyelina-
tion of axons. Four days after lysolecithin-induced demyelination,
immunostaining for the myelin marker MBP still appeared sparse
when sliceswere cultured inmediumwithout the addition of prog-
estins. However, in slices cultured for 4 days in the presence of
progesterone, there was a marked increase in MBP immunoreac-
tive processes (Hussain et al., 2011). Similarly, when cerebellar
slices were exposed to the potent fourth-generation progestin
Nestorone, designed to selectively target intracellular PR, dense
networks of well-organized myelinated ﬁbers were observed. In
contrast, another progestin used in contraception and hormone
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replacement therapy (HRT), the 17-OH progesterone derivative
MPA had no signiﬁcant effect on the formation of new myelin
sheaths. This study also revealed that progestins promote the
formation of new myelin sheaths via pleiotropic inﬂuences on
the proliferation, migration, and differentiation of OPC (Hussain
et al., 2011).
As for the effect of progesterone on developmental myelina-
tion, remyelination by Nestorone involved PR, as it was observed
inwild-type PR+/+ mice, but not in homozygous knockout PR−/−
mice (Hussain et al., 2011; Figure 4B). Remarkably, the use of
transgenic mice allowed the identiﬁcation of PR as a limiting
factor for the stimulating effects of progesterone on both develop-
mental myelination and remyelination. Indeed, for both processes,
progesterone was less efﬁcient in promoting the formation of new
myelin sheaths in heterozygous PR+/−when compared to wild-
type PR+/+ mice (Figure 4; Ghoumari et al., 2003; Hussain et al.,
2011). These results provide evidence for PR haploinsufﬁciency
in myelination and myelin repair, as the target tissues of prog-
esterone in PR+/− mice contain about half of the number of PR
binding sites when compared with PR+/+ mice (Lydon et al., 1995;
Mani et al., 1997). This contrasts with the reproductive functions
of PR, for which decreased PR expression, as observed in PR+/−
mice, does not result in a particular phenotype (Mani et al., 1997).
Moreover, it has been suggested that only part of hypothalamic
PR needs to be activated for maximal levels of sexual receptivity
in female rats (Pfaff and McEwen, 1983).
In vivo, a beneﬁcial inﬂuence of progesterone treatment on the
replacement of lost myelin was shown in middle-aged male rats
(9months old) after toxin-induced demyelination of the caudal
cerebellar peduncle (Ibanez et al., 2003b, 2004). The rationale for
using males in this study was that they have constant low levels
of endogenous progesterone, contrasting with the cyclic varia-
tions in females. Older animals were used because aging markedly
reduces the endogenous capacity of the brain to repairmyelin. This
age-related decline in remyelination efﬁciency has been shown
to result from both an impairment of oligodendrocyte progeni-
tor recruitment and differentiation (Sim et al., 2002). Five weeks
after creating a focal area of demyelination in cerebellar pedun-
cle by the stereotaxic infusion of ethidium bromide, the extent
of spontaneous remyelination was indeed considerably less to
that seen in young 10-week-old males. However, treatment of
the older males with subcutaneous pellets of progesterone, pro-
ducing constant elevated levels of the hormone (about 40 nM),
signiﬁcantly increased the percentage of myelinated axons. As a
benchmark, progesterone levels in pregnant rodents reach about
600 nM (Meffre et al., 2007b). Although remyelination in the
progesterone-treated animals was not extensive, approximately
20% of the axons within the lesion, it nevertheless constituted
a doubling of the proportion of remyelinated axons when com-
pared to the vehicle-treated control group (Ibanez et al., 2004).
This can be considered as a very encouraging result, given that
remyelination in older animals has proven remarkably refrac-
tory to remyelinating therapeutic approaches (O’Leary et al.,
2002).
It is important not to forget that under normal physiologi-
cal conditions, progesterone does not act alone on target cells,
but often in a cooperative manner with estradiol. This goes back
to pioneering studies in the early 1980s showing that estradiol
treatment increases PR expression in the hypothalamus, and that
the time course of the induction of PR by estradiol parallels the
time course of the induction of behavioral responsiveness to prog-
esterone (Blaustein and Feder, 1979; Parsons et al., 1980). A recent
immunoelectron microscopy study has revealed that the abundant
PR labeling in neurites and glial cells in extra-hypothalamic sites
such as the hippocampus is also strongly dependent on estrogen
priming (Waters et al., 2008). Likewise, in primary cultures of glial
cells prepared fromneonatal rat brains,PR expressionwas upregu-
lated by adding estradiol to the culture medium (Jung-Testas et al.,
1991).
That estradiol can potentiate the promyelinating effect of prog-
esterone has recently been shown in an experimental model
of cuprizone-induced demyelination. Feeding mice the copper
chelator cuprizone leads to the apoptosis of oligodendrocyte and
the demyelination of axons, which are spared (Matsushima and
Morell, 2001). Whereas combined treatment of young male mice
with estradiol and progesterone counteracted the loss of myelin in
response to cuprizone intoxicationwithin the corpus callosum, the
individual application of each steroid only resulted in a moderate
prevention of demyelination (Acs et al., 2009). These observations
strongly suggest that progestagens may protect oligodendrocytes
and promotemyelin repair by acting in concertwith estrogens, and
they point to an increased efﬁcacy of combined progestagen and
estrogen administration for treating demyelinating conditions.
Thus, future experimental studies on myelination and remyeli-
nation should pay more attention to the combined actions of both
hormones. Progesterone and estradiol may directly exert com-
bined effects on oligodendrocytes. Thus, both steroids promoted
the differentiation of oligodendrocyte progenitors in culture, but
whereas progesterone increased cellular branching, estradiol stim-
ulated myelin sheath formation (Marin-Husstege et al., 2004). In
addition, the cooperation between progesterone and estradiol may
indirectly exert beneﬁcial inﬂuences on myelin repair by regulat-
ing energy supply andneuroinﬂammatory responses via astrocytes
(Kipp and Beyer, 2009).
An important experimental disease model of multiple sclerosis,
which has allowed the evaluation of many medications, is exper-
imental autoimmune encephalomyelitis (EAE; Lassmann, 2008;
Stuve et al., 2010). It can be induced in animals by sensitization
to myelin antigens (active EAE) or by the transfer of autoreac-
tive T cells (passive EAE). Whereas the above described models of
toxin-induced demyelination are valuable to address treatment
effects on myelin repair, EAE models are particularly suitable
for studying treatment effects on autoimmune and inﬂammatory
responses to demyelination. Beneﬁcial effects on disease severity
in EAE have been mainly studied for the estrogens. These stud-
ies were motivated by the idea that the immunomodulatory and
anti-inﬂammatory actions of the estradiol may have a beneﬁcial
inﬂuence on EAE symptoms (Offner, 2004). When administered
prior to EAE induction, estrogens delay the onset of symptoms and
reduce disease activity. Their immunoprotective effects involve
the α isoform of the estrogen receptor (ER; Liu et al., 2003).
The mechanisms underlying these beneﬁcial effects most likely
involve a wide range of targets and actions. Thus, estrogens have
been shown to inhibit the activity of myelin-reactive T cells and
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inﬂammatory responses in the brain (Bebo Jr. et al., 2001). A key
role of macrophages and microglia in the modulation of immune
responses by estrogens has been demonstrated by cell-speciﬁc ER
disruption (Calippe et al., 2010). More recently, it was shown that
the beneﬁcial effects of ERα ligand treatment on CNS inﬂamma-
tion, axonal loss, and neurological outcomes can be prevented by
conditional deletion of ERα from astrocytes. In contrast, deletion
of ERα from neurons had no signiﬁcant effect, pointing to a key
role of ERα signaling in astrocytes (Spence et al., 2011).
In comparison with estradiol, the effects of progesterone in
EAE have attracted much less attention. However, various types
of immune cells express PR, and during pregnancy, progesterone
contributes to the establishment of a protective immune envi-
ronment by modulating multiple immune responses, including a
shift away from the production of Th1 pro-inﬂammatory to Th2
anti-inﬂammatory cytokines (De Leon-Nava et al., 2009; Szekeres-
Bartho et al., 2009). Regulation of the Th1/Th2 balance by prog-
esterone may play an important role in multiple sclerosis and may
contribute to the improvement of disease symptoms during preg-
nancy and their post-partum worsening (Confavreux et al., 1998).
Treating female mice with subcutaneous implants of progesterone
starting 1week prior to EAE induction attenuated disease severity,
and reduced inﬂammatory responses and demyelination in the
spinal cord (Garay et al., 2007). Importantly, progesterone also
decreased axonal damage and restored the expression of vital neu-
ronal genes (Garay et al., 2009). Whereas estrogens may need to be
administered before the induction of EAE,progesterone treatment
initiated as late as 2 weeks after immunization with myelin protein
peptide still exerted beneﬁcial effects, suggesting a larger thera-
peutic window (Yates et al., 2010; Yu et al., 2010). However, not
all studies have reported beneﬁcial effects of progestagens on EAE
symptoms (Kim et al., 1999; Hoffman et al., 2001). Thus, the syn-
thetic progestin MPA, which in contrast to natural progesterone
failed to stimulate myelin formation in cerebellar slice cultures,
has been reported to increase the severity of EAE (Arnason and
Richman, 1969).
THE SIGNIFICANCE OF PROGESTAGENS IN MULTIPLE
SCLEROSIS
Whereas experimental animal studies point to considerable inﬂu-
ences of steroids, and in particular of progesterone and estradiol,
on demyelinating diseases such asmultiple sclerosis, clinical obser-
vations have so far provided insufﬁcient or only indirect evidence.
A strong indirect argument in favor of hormonal inﬂuences on
multiple sclerosis is provided by the observed sex differences in
the incidence and course of the disease, and by the pregnancy-
associated changes in the relapse rate. Thus, according to a cross-
sectional study conducted in France, the women–men ratio of
multiple sclerosis is 2.6 (Fromont et al., 2010). Intriguingly, the
gap between sexes in the incidence of the disease has increased over
the last decades (Noonan et al., 2002; Bentzen et al., 2010). The
course of multiple sclerosis is noticeably inﬂuenced by pregnancy.
Thus, the rate of relapses is reduced during the last 3months of
pregnancy, when circulating levels of progesterone and estrogens
are highest, but it is markedly increased during the ﬁrst 3months
post-partum, after a drop in sex steroid levels (Confavreux et al.,
1998).
Changes in multiple sclerosis symptoms related to the men-
strual cycle or menopause are not sufﬁciently documented and
require further evaluation (El-Etr et al., 2011). Also, little is known
about the inﬂuence of oral contraceptives or postmenopausalHRT
on the course of the disease. Taken together, clinical observations
point to a protective effect of hormone treatments, but there is
a need for large prospective studies (El-Etr et al., 2011). In 2005,
a double-blind and placebo-controlled study, named Popart’mus,
has been launched to test the combined efﬁcacy of the synthetic
19-nor-progestatif nomegestrol acetate (Lutenyl), taken orally, and
of transdermal estradiol patches, in reducing post-partum relapses
in women with multiple sclerosis (Vukusic et al., 2009).
An important role of perturbed neurosteroidogenesis in
demyelinating diseases has been suggested by a recent study. The
expression of enzymes involved in neurosteroid biosynthesis and
levels of neurosteroids were found to be dysregulated in the white
matter of patients with multiple sclerosis and in a related mouse
EAE disease model. In particular, 3α-HSD expression and brain
allopregnanolone levels were decreased. Importantly, treatment of
EAEmicewith allopregnanolone improved behavioral deﬁcits and
neuropathological changes (Noorbakhsh et al., 2011).At the origin
of this discovery was a high-throughput proﬁling of micro-RNA
in white matter of patients with or without multiple sclerosis.
The analysis revealed in the multiple sclerosis patients a strong
upregulationof threemicro-RNAs, speciﬁcally involved in the sup-
pression of genes coding for steroidogenic enzymes (Noorbakhsh
et al., 2011).
DISCUSSION OF THERAPEUTIC OPTIONS WITH
PROGESTERONE AND PROGESTINS
An important role of progesterone in the generation of new oligo-
dendrocytes and in the replacement of lost myelin opens new
therapeutic opportunities for demyelinating diseases. Treatment
with a progestin is obviously an option for women with multi-
ple sclerosis, as in the ongoing Popart’mus trial (Vukusic et al.,
2009). However, the administration of a progestin, in combi-
nation with an androgen, may also be considered in men with
multiple sclerosis. Thus, combination of a progestin and an andro-
gen is currently tested for male hormonal contraception. Such
combined treatments indeed provide efﬁcient suppression of sper-
matogenesis, and they are efﬁcacious, reversible, and well tolerated
(Wang and Swerdloff, 2010). Thus, the transdermal administra-
tion of Nestorone and testosterone has been demonstrated to be
safe and effective for the suppression of gonadotropins in men
(Mahabadi et al., 2009). In this study,Nestorone was administered
as a transdermal gel as it is orally inactive (Kumar et al., 2000).
The identiﬁcation of PR as a therapeutic target for promoting
myelination and myelin repair suggests new therapeutic bene-
ﬁts for contraceptive progestins, and in particular for fourth-
generation 19-nor-progestatifs, speciﬁcally designed to speciﬁcally
target the intracellular PR (Nestorone,nomegestrol acetate).How-
ever, it is important to call here attention to the fact that not all
synthetic progestins are the same, and that they belong to dif-
ferent classes with very distinct pharmacological properties and
actions (Stanczyk, 2003; Hapgood et al., 2004; Schumacher et al.,
2007, 2008). Thus,whereas Nestorone promotes myelin repair and
has neuroprotective properties, the progestin MPA is devoid of
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such beneﬁcial effects and can even become harmful for neural
cells (Liu et al., 2010; Hussain et al., 2011). Indeed, in contrast to
natural progesterone and Nestorone, the synthetic 17-OH proges-
terone derivative MPA was inefﬁcient in stimulating the formation
of new myelin sheaths in organotypic cultures of cerebellar slices
(Hussain et al., 2011). Likewise, whereas progesterone has a ben-
eﬁcial inﬂuence on EAE, the administration of MPA increased
disease severity (Arnason and Richman, 1969).
In addition to progestins currently used for contraceptive
purposes and HRT, selective progesterone receptor modulators
(SPRM),which display different activities in a tissue-speciﬁc man-
ner,deservemore attention,and it has becomeurgent to study their
effects on neural cells (Bouchard et al., 2011).
An important question, then, is whether it is meaningful to
focus on the therapeutic promises of synthetic progestins for the
treatment of demyelinating diseases, or whether the use of nat-
ural (bioidentical) progesterone should be preferred? Progestins
are deﬁnitely an option, and an obvious advantage of certain
synthetic compounds is their great selectivity and efﬁcacy. Thus,
due to their high potency, very low doses of some progestins
may be sufﬁcient and may be delivered via long-term sustained-
release delivery systems (Sitruk-Ware et al., 2003). On the other
hand, natural progesterone may offer a better beneﬁt/risk ratio for
prolonged treatments than synthetic progestins. This is strongly
suggested by results of the large French E3N prospective cohort
study, showing that in contrast to HRT with progestins, the use of
natural micronized progesterone is not associated with an increase
in breast cancer or thrombotic risk (Fournier et al., 2008;Canonico
et al., 2010).
Natural progesterone, tested in most experimental preclinical
studies, may also offer a wider range of beneﬁts than the more
selective progestins. Indeed, progesterone exerts multiple beneﬁ-
cial effects on the nervous system, which may not be mimicked
all by synthetic compounds. First, some of the effects of proges-
terone in the nervous system, including its neuroprotective and
psychopharmacological actions, are mediated by its neuroactive
metabolites, and in particular by allopregnanolone (Grifﬁn et al.,
2004; Belelli and Lambert, 2005; Sayeed et al., 2006; Wang et al.,
2008). In contrast, synthetic progestins are not converted to allo-
pregnanolone and no information is currently available in the
literature concerning their metabolism in the brain or other target
tissues (Schumacher et al., 2007). Second, research over the past
years has revealed multiple targets of progesterone in the nervous
system, ranging from the intracellular PR to the recently cloned
membrane PR. Not all the progesterone targets may bind syn-
thetic progestins, initially designed to target the classical PR. For
example, a series of progestins which bind with high selectivity
and afﬁnity to the intracellular PR do not bind to the human
membrane PR α isoform (Thomas et al., 2007). Such considera-
tions may have encouraged the use of natural progesterone in two
recent phase II trials aimed to evaluate the efﬁcacy of progesterone
as a neuroprotective agent in TBI patients (Wright et al., 2007; Xiao
et al., 2008).
There is however a major problem with the use of natural
progesterone. Indeed, ﬁrst-pass metabolism in the digestive tract
and liver make supplementing with oral progesterone difﬁcult.
One option is the use of micronized progesterone, widely used
in Europe, and in particular in France, since 1980. Micronized
progesterone is natural progesterone, whose average particle size
has been reduced, leading to decreased destruction in the gas-
trointestinal tract, longer half-life, enhanced bioavailability, and
efﬁcacy (Schumacher et al., 2007). Its use is well tolerated, with
mild, and transient sedation as a side effect that can be minimized
by taking the hormone at bedtime (de Lignieres, 1999). However,
even aftermicronization, a large proportion of orally administered
progesterone is metabolized by the liver. Thus, there is much inter-
est for other routes of progesterone administration. In the above
mentioned neuroprotective trials, progesterone was administered
to TBI patients either intravenously (the Atlanta study: Wright
et al., 2007) or by intramuscular injections (the Hangzhou study:
Xiao et al., 2008). However, these modes of administration are
only suitable for acute treatments, and they are difﬁcult to imple-
ment in emergency cases.An alternative option for the longer-term
treatment of patients with demyelinating diseases is the delivery of
progesterone by transdermal or vaginal gels, allowing the hormone
to reach its target tissues prior to its metabolism by the liver.
Nasal administration of natural progesterone has received
attention as an alternative to speciﬁcally target the brain (Costan-
tino et al., 2007). The intranasal route of administration could
offer the possibility of achieving the desired brain concentration of
progesterone required for myelin repair and neuroprotection, and
could offer interesting perspectives both for the efﬁcient acute and
long-term use of natural progesterone (Ducharme et al., 2010).
Thus, intranasally administered progesterone has been shown to
rapidly enhance dopamine levels within speciﬁc brain regions (de
Souza Silva et al., 2008).
Although most of the pleiotropic effects of progesterone in the
nervous system have been reported to be beneﬁcial, there may be
a few particular pathological conditions for which progesterone
may exert deleterious effects. This is the case for the hereditary
neuropathy CMT1A,where progesterone further increases expres-
sion of the mutated disease gene PMP22 (Sereda et al., 2003). For
this disease, treatment with a PR antagonist or with a SPRM is a
therapeutic option.
Progesterone present in the brain is either derived from the
steroidogenic endocrine glands or form local synthesis. From this
concept derives another therapeutic option for treating degener-
ative diseases and lesions of the nervous system: stimulating the
synthesis of endogenous progesterone and its metabolites in the
brain. In this regard, TSPO ligands offer new therapeutic promises
(Papadopoulos et al., 2006; Papadopoulos and Lecanu, 2009; Rup-
precht et al., 2010). It has indeed been proposed that TSPO ligands
may be valuable in the treatment of neurological and psychiatric
disorders (Rupprecht et al., 2010). Experimental animal studies
have revealed that TSPO expression is upregulated in EAE and
after cuprizone-induced demyelination. Interestingly, TSPO levels
remains elevated during the period of myelin repair, suggesting
a role of the protein the remyelination of axons (Agnello et al.,
2000; Chen et al., 2004). Moreover, increased TSPO expression
in astrocytes was associated with increased brain levels of prog-
esterone in dysmyelinating mouse mutants (Le Goascogne et al.,
2000).
In conclusion, multiple therapeutic approaches remain to be
further explored for promoting myelin repair with progestagens
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in demyelinating diseases or after injury. The administration of
synthetic progestins and natural progesterone are both interesting
options. An important question is their mode of administration.
Nasal application, easy to implement for efﬁcient delivery of prog-
esterone into the brain, deserves particular attention. Because
natural progesterone is converted in the brain to neuroactive
metabolites, and because the hormone targets multiple signaling
mechanisms, its future use for the treatment of demyelinating
diseases, and other neurological disorders should be considered.
Stimulating the production of endogenous neuroprogesterone in
the nervous system with TSPO ligands offers new perspectives for
remyelinating and neuroprotective interventions.
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